CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with ...
Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight
Multiple Sclerosis companies are Immune Response BioPharma, Clene Nanomedicine, Genzyme, ImStem Biotechnology, Rho, Inc., ...
MPM BioImpact Appoints Brian Shuster, Experienced in Healthcare Corporate Development, as Entrepreneur Partner
MPM BioImpact, a biotechnology investment firm creating and investing in innovative companies seeking to deliver ...
Hosted on MSN28m
Merck Just Paid Investors: How Much Did They Receive?
Merck & Co. Inc. (NYSE: MRK) is rewarding its shareholders once again with a quarterly dividend of $0.81 per share, payable ...
Aer Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Fexlamose in Chronic Obstructive Pulmonary Disease
Study AER-01-002 is using a novel and precision imaging strategy to enroll 100 mucus plug-high chronic obstructive pulmonary disease (COPD) ...
Le Lézard54m
Microbix Expanding Addressable Market Share with Test Makers Augmenting its Recombinant Antigen Capabilities for Immunoassay Markets
Microbix Biosystems Inc. , a life sciences innovator, manufacturer, and exporter, announces its intentions to broaden its platform capabilities to enable production of a wider range of test ...